EF-14 PIVOTAL TRIAL: TREATING A NEWLY-DIAGNOSED GLIOBLASTOMA WITH OPTUNE
During the EF-14 phase III pivotal trial, 695 patients of both sexes with a newly-diagnosed glioblastoma were investigated. They had first undergone surgery, then combined chemoradiotherapy that included the administration of temozolomide (TMZ). Subsequently, the patients were treated either with temozolomide maintenance therapy alone or with the addition of Optune (Optune + TMZ).
The results of the EF-14 study show that combining Optune and TMZ is significantly more beneficial than TMZ therapy alone. Combined therapy with Optune + TMZ significantly prolongs the median overall survival compared to therapy with TMZ only.
Median overall survival is significantly prolonged
During the long-term analysis of the EF-14 study, the median overall survival from the time of randomization for patients treated with Optune + TMZ was 20.9 months, compared to 16.0 months in the group treated with TMZ alone.
The data also show that combined therapy with Optune + TMZ may significantly prolong the survival of patients with newly-diagnosed GBM over 5 years as opposed to TMZ therapy only.